Lisdexamfetamine (NRP104, Shire/New River Pharmaceuticals) for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)
Approvable designations
Fast-track designations
Orphan drug designations
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More